Potential application of a chemically modified non-antimicrobial tetracycline (CMT-3) against metastatic prostate cancer.
Lokeshwar
B L
BL
Department of Urology, University of Miami School of Medicine, Florida 33101, USA.
Houston-Clark
H L
HL
Selzer
M G
MG
Block
N L
NL
Golub
L M
LM
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D004318:Doxycycline / Q000494:pharmacology / Q000627:therapeutic use; D004347:Drug Interactions; D004847:Epithelial Cells / Q000187:drug effects; D005480:Flurbiprofen / Q000494:pharmacology; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000556:secondary*; D008297:Male; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000201:enzymology / Q000473:pathology*; D011480:Protease Inhibitors / Q000494:pharmacology*; D051381:Rats; D012044:Regression Analysis; D013754:Tetracyclines / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use*; D014407:Tumor Cells, Cultured / Q000187:drug effects